Regulation of Melanogenesis by the Amino Acid Transporter SLC7A5.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
11 2020
Historique:
received: 06 12 2019
revised: 26 02 2020
accepted: 09 03 2020
pubmed: 3 4 2020
medline: 7 4 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Integration of chromatin immunoprecipitation-sequencing and microarray data enabled us to identify previously unreported MITF-target genes, among which the amino acid transporter SLC7A5 is also included. We reported that small interfering RNA-mediated SLC7A5 knockdown decreased pigmentation in B16F10 cells but neither affected morphology nor dendricity. Treatment with the SLC7A5 inhibitors 2-amino-2-norbornanecarboxylic acid (BCH) or JPH203 also decreased melanin synthesis in B16F10 cells. Our findings indicated that BCH was as potent as reference depigmenting agent, kojic acid, but acted through a different pathway not affecting tyrosinase activity. BCH also decreased pigmentation in human MNT1 melanoma cells or normal human melanocytes. Finally, we tested BCH on a more physiological model, using reconstructed human epidermis and confirmed a strong inhibition of pigmentation, revealing the clinical potential of SLC7A5 inhibition and positioning BCH as a depigmenting agent suitable for cosmetic or dermatological intervention in hyperpigmentation diseases.

Identifiants

pubmed: 32240722
pii: S0022-202X(20)31209-4
doi: 10.1016/j.jid.2020.03.941
pii:
doi:

Substances chimiques

2-amino-2-norbornanecarboxylic acid 0
Carboxylic Acids 0
Large Neutral Amino Acid-Transporter 1 0
Melanins 0
Microphthalmia-Associated Transcription Factor 0
Norbornanes 0
Pyrones 0
RNA, Small Interfering 0
kojic acid 6K23F1TT52

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2253-2259.e4

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Céline Gaudel (C)

Nunii Laboratoire, Grasse Biotech, Grasse, France; Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

Frédéric Soysouvanh (F)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

Justine Leclerc (J)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

Karine Bille (K)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

Chrystel Husser (C)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

François Montcriol (F)

Nunii Laboratoire, Grasse Biotech, Grasse, France.

Corine Bertolotto (C)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France.

Robert Ballotti (R)

Université Nice Côte d'Azur, C3M, INSERM, U1065, Biology and pathologies of melanocytes, Nice, France. Electronic address: ballotti@unice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH